Adial Net Income From Continuing Ops from 2010 to 2026

ADIL Stock  USD 0.22  0.01  4.35%   
Adial Pharmaceuticals Net Loss yearly trend continues to be quite stable with very little volatility. The value of Net Loss is projected to decrease to about -12.5 M. From the period between 2010 and 2026, Adial Pharmaceuticals, Net Loss regression line of its data series had sample variance of 39.5 T and sample variance of 39.5 T. View All Fundamentals
 
Net Loss  
First Reported
2015-12-31
Previous Quarter
-2 M
Current Value
-1.8 M
Quarterly Volatility
1.8 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Adial Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adial Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 215.7 K, Depreciation And Amortization of 617 or Interest Expense of 758.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.36. Adial financial statements analysis is a perfect complement when working with Adial Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Adial Stock
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

Latest Adial Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Adial Pharmaceuticals over the last few years. It is Adial Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adial Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Adial Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(6,874,547)
Coefficient Of Variation(91.41)
Mean Deviation5,709,267
Median(8,591,429)
Standard Deviation6,283,952
Sample Variance39.5T
Range19M
R-Value(0.83)
Mean Square Error13.2T
R-Squared0.69
Significance0.00004
Slope(1,030,914)
Total Sum of Squares631.8T

Adial Net Income From Continuing Ops History

2026-12.5 M
2025-11.9 M
2024-13.2 M
2023-9.6 M
2022-12.7 M
2021-19.4 M
2020-10.9 M

About Adial Pharmaceuticals Financial Statements

Adial Pharmaceuticals investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Adial Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-11.9 M-12.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.60)
Return On Assets
(0.79)
Return On Equity
(1.55)
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.